Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MB Software has reported that its wholly owned subsidiary Wound Care Innovations has acquired the exclusive worldwide license to market and sell the current and any new developed external wound care products for the human health care market.
Subscribe to our email newsletter
The company has been marketing the CellerateRx brand of products within the US to the human health care market. CellerateRx is available in two forms, a powder and a gel, and both products feature HCPCS codes for reimbursement in the US.
Scott Haire, chairman of MB Software (MBSB), said: “These enhanced agreements coupled with our recent announcement of evidence-based studies on the Cellerate products will give us greater momentum going into 2008 and beyond.”